# A Phase I/II Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of the EMB-07 Combination Therapy in Patients With Aggressive B-Cell Non-Hodgkin Lymphoma

> **NCT07432022** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Shanghai EpimAb Biotherapeutics Co., Ltd.** · enrollment: 115 (estimated)

## Conditions studied

- Combination Therapy
- Aggressive B-Cell Non-Hodgkin Lymphoma
- EMB07
- phaseI/II

## Interventions

- **DRUG:** EMB07
- **DRUG:** Rituximab/Gemcitabine/Oxaliplatin

## Key facts

- **NCT ID:** NCT07432022
- **Lead sponsor:** Shanghai EpimAb Biotherapeutics Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-01
- **Primary completion:** 2028-06-30
- **Final completion:** 2028-06-30
- **Target enrollment:** 115 (ESTIMATED)
- **Last updated:** 2026-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07432022

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07432022, "A Phase I/II Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of the EMB-07 Combination Therapy in Patients With Aggressive B-Cell Non-Hodgkin Lymphoma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07432022. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*